Rybelsus 14mg tablet contains active components such as Semaglutide. This medication belongs to a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This medication treats type 2 diabetes by lowering blood sugar levels and promoting weight loss. It also reduces the risk of cardiovascular events in high-risk diabetes patients. It can be combined with other diabetes medications for better control and may lower blood pressure, benefitting cardiovascular health. Additionally, it shows potential in protecting kidneys and slowing diabetic kidney disease progression.

You should not take Rybelsus 14mg tablet if you have a known hypersensitivity to this medication or any of its components. People with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) should not take this medication. It is not approved for use in pediatric patients with type 2 diabetes. It should not used in individuals with a history of severe gastrointestinal disease, such as gastroparesis. This medication is not recommended for individuals with severe renal impairment or end-stage renal disease.

Type 2 diabetes mellitus.

Obesity or overweight.

Rybelsus 14mg tablet, a GLP-1 receptor agonist, exerts its therapeutic effects by mimicking the action of the naturally occurring hormone GLP-1. In diabetes management, this medication enhances insulin secretion, inhibits glucagon release, slows gastric emptying, and decreases hepatic glucose production. This medication effect leads to improved glycemic control and reduced HbA1c levels. Additionally, this medication promotes weight loss through increased satiety, decreased food intake, and modulation of gastric function. It has also demonstrated cardiovascular benefits, including a potential reduction in major cardiovascular events.

Rybelsus 14mg tablet is typically administered as a subcutaneous injection. The injection can be given in the abdomen, thigh, or upper arm. These medication pens come with clear instructions on how to load the needle, dial the dose, and administer the injection. After injecting, dispose of the needle safely in a sharps container. Regular monitoring and follow-up with your healthcare provider are important to assess your progress and make any necessary adjustments to your treatment plan.

Allergic reactions

Pancreatitis (abdominal pain, nausea, vomiting)

Hypoglycemia (low blood sugar)

Kidney problems (changes in urination, swelling in the ankles or feet)

Thyroid C-cell tumors

Nausea

Vomiting

Diarrhea

Constipation

Abdominal pain

Decreased appetite

Headache

Fatigue

Injection site reactions (e.g., redness, pain, itching)

Inform the doctor about your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Rybelsus 14mg tablet, reducing effectiveness by causing undesirable side effects.

Stored in a refrigerator from 2°C to 8°C.

Keep away from moisture, heat, and light.

It should not be frozen.

Keep away from children and pets.

Discuss your medical history with your healthcare provider, especially if you have a history of pancreatitis, thyroid issues, kidney or liver problems, or gallbladder disease. Monitor your blood sugar levels regularly to avoid hypoglycemia, particularly when taking other antidiabetic medications. Adhere strictly to the prescribed dosage and injection schedule, and follow proper injection techniques to minimize risks. Its injections may cause skin reactions at the injection site. Rotate injection sites and follow proper injection techniques to minimize this risk. Report any unusual symptoms, such as abdominal pain or skin reactions, promptly to your healthcare provider. Pregnant and breastfeeding women should consult a doctor before taking this medication. Regularly assess your overall health and any potential changes while using Rybelsus 14mg tablet, and attend follow-up appointments as your healthcare provider recommends.